Targeting the ABCB4 gene to control cholesterol homeostasis

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 10, 2011, Pages 1173-1182

  Oude Elferink, Ronald Pj ^a   Beuers, Ulrich ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Bile; bile acids; bile salts; cholesterol; FXR; gallstones; phospholipids; progressive familial intrahepatic cholestasis; reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; URSODEOXYCHOLIC ACID;

BILE FLOW; CRITICAL MICELLE CONCENTRATION; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BILIARY TRACT; CHOLESTEROL; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; INTESTINES; LLC-PK1 CELLS; MICE; P-GLYCOPROTEINS; STEROLS; SWINE;

EID: 80052902544     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.607163     Document Type: Review

References (71)

1. Morotti RA, Suchy FJ, Magid MS. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis 2011;31:3-10
2. Davit-Spraul A, Gonzales E, Baussan C, et al. The spectrum of liver diseases related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver Dis 2010;30:134-46
3. Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflugers Arch 2007;453:601-10 (Pubitemid 46192533)
4. Trauner M, Fickert P, Wagner M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis 2007;27:77-98
5. Oude Elferink RP, Ottenhoff R, van Wijland M, et al. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest 1995;95:31-8
6. Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipids from bile and to liver disease. Cell 1993;75:451-62 (Pubitemid 23335071)
7. Smith AJ, Timmermans-Hereijgers JL, Roelofsen B, et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 1994;354:263-6
8. van Helvoort A, Smith AJ, Sprong H, et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 1996;87:507-17 (Pubitemid 26374324)
9. Morita SY, Kobayashi A, Takanezawa Y, et al. Bile salt-dependent efflux of cellular phospholipids mediated by ATP binding cassette protein B4. Hepatology 2007;46:188-99 (Pubitemid 47171936)
10. Wiersma H, Gatti A, Nijstad N, et al. Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice. Hepatology 2009;50:1263-72
11. Oude Elferink RP, Ottenhoff R, van Wijland M, et al. Uncoupling of biliary phospholipid and cholesterol secretion in mice with reduced expression of mdr2 P-glycoprotein. J Lipid Res 1996;37:1065-75 (Pubitemid 26182339)
12. Oude Elferink RP, Paulusma CC, Groen AK. Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 2006;130:908-25 (Pubitemid 43374538)
13. Yoshikado T, Takada T, Yamamoto T, et al. Itraconazole-induced cholestasis: involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4. Mol Pharmacol 2011;79:241-50
14. Smit JJ, Schinkel AH, Mol CA, et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 1994;71:638-49 (Pubitemid 24374570)
15. Patel P, Weerasekera N, Hitchins M, et al. Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C,OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta 2003;24:39-44 (Pubitemid 37184694)
16. Augustine LM, Markelewicz RJ Jr, Boekelheide K, et al. Xenobiotic and endobiotic transporter mRNA expression in the blood-testis barrier. Drug Metab Dispos 2005;33:182-9 (Pubitemid 40023530)
17. Cui YJ, Cheng X, Weaver YM, et al. Tissue distribution, gender-divergent expression, ontogeny, and chemical induction of multidrug resistance transporter genes (Mdr1a, Mdr1b, Mdr2) in mice. Drug Metab Dispos 2009;37:203-10
18. Kim WS, Weickert CS, Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 2008;104:1145-66 (Pubitemid 351293350)
19. Pennings M, Hildebrand RB, Ye D, et al. Bone marrow-derived multidrug resistance protein ABCB4 protects against atherosclerotic lesion development in LDL receptor knockout mice. Cardiovasc Res 2007;76:175-83 (Pubitemid 47362036)
20. Frijters CM, Ottenhoff R, van Wijland MJ, et al. Regulation of mdr2 P-glycoprotein expression by bile salts. Biochem J 1997;321:389-95 (Pubitemid 27056485)
21. Gupta S, Todd SR, Pandak WM, et al. Regulation of multidrug resistance 2 P-glycoprotein expression by bile salts in rats and in primary cultures of rat hepatocytes. Hepatology 2000;32:341-7 (Pubitemid 30614666)
22. Jung D, Elferink MG, Stellaard F, et al. Analysis of bile acid-induced regulation of FXR target genes in human liver slices. Liver Int 2007;27:137-44 (Pubitemid 46139438)
23. Liu Y, Binz J, Numerick MJ, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 2003;112:1678-87 (Pubitemid 38063725)
24. Huang L, Zhao A, Lew JL, et al. Farnesoid X receptor activates transcription of the phospholipid pumpMDR3. J Biol Chem 2003;278:51085-90 (Pubitemid 38020343)
25. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005;129:476-85 (Pubitemid 41096635)
26. Chianale J, Vollrath V, Wielandt AM, et al. Fibrates induce mdr2 gene expression and biliary phospholipids secretion in the mouse. Biochem J 1996;314(Pt 3):781-6 (Pubitemid 26097736)
27. Shoda J, Okada K, Inada Y, et al. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 2007;37:548-56 (Pubitemid 46864251)
28. Kok T, Bloks VW, Wolters H, et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. Biochem J 2003;369:539-47 (Pubitemid 36246237)
29. Matsumoto T, Miyazaki H, Nakahashi Y, et al. Multidrug resistance 3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004;30:125-36 (Pubitemid 39654742)
30. Kanda T, Yokosuka O, Imazeki F, et al. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003;38:573-8 (Pubitemid 36857389)
31. Kurihara T, Niimi A, Maeda A, et al. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000;95:2990-2
32. Roglans N, Vazquez-Carrera M, Alegret M, et al. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients. Eur J Clin Pharmacol 2004;59:855-61 (Pubitemid 38333675)
33. Shoda J, Inada Y, Tsuji A, et al. Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. J Lipid Res 2004;45:1813-25 (Pubitemid 40990873)
34. Nakamuta M, Fujino T, Yada R, et al. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipids secretion via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther 2010;48:22-8
35. Wang J, Sun F, Zhang DW, et al. Sterol transfer by ABCG5 and ABCG8: in vitro assay and reconstitution. J Biol Chem 2006;281:27894-904 (Pubitemid 44414501)
36. Wang J, Zhang DW, Lei Y, et al. Purification and reconstitution of sterol transfer by native mouse ABCG5 and ABCG8. Biochemistry 2008;47:5194-204 (Pubitemid 351620756)
37. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000;290:1771-5 (Pubitemid 32004809)
38. Tauscher A, Kuver R. ABCG5 and ABCG8 are expressed in gallbladder epithelial cells. Biochem Biophys Res Commun 2003;307:1021-8 (Pubitemid 36871675)
39. Repa JJ, Berge KE, Pomajzl C, et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J Biol Chem 2002;277:18793-800 (Pubitemid 34952438)
40. Plosch T, van der V, Havinga R, et al. Abcg5/Abcg8-independent pathways contribute to hepatobiliary cholesterol secretion in mice. Am J Physiol Gastrointest Liver Physiol 2006;291:G414-23 (Pubitemid 44330161)
41. Freeman LA, Kennedy A, Wu J, et al. The orphan nuclear receptor LRH-1 activates the ABCG5/ ABCG8 intergenic promoter. J Lipid Res 2004;45:1197-206 (Pubitemid 38802623)
42. Sumi K, Tanaka T, Uchida A, et al. Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and ABCG8. Mol Cell Biol 2007;27:4248-60 (Pubitemid 46906550)
43. Vrins C, Vink E, Vandenberghe KE, et al. The sterol transporting heterodimer ABCG5/ABCG8 requires bile salts to mediate cholesterol efflux. FEBS Lett 2007;581:4616-20 (Pubitemid 47418786)
44. Klett EL, Lu K, Kosters A, et al. A mouse model of sitosterolemia: absence of Abcg8/sterolin-2 results in failure to secrete biliary cholesterol. BMC Med 2004;2:5
45. Yu L, Hammer RE, Li-Hawkins J, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliarycholesterol secretion. Proc Natl Acad Sci USA 2002;99:16237-42 (Pubitemid 35462779)
46. Yu L, Gupta S, Xu F, et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem 2004;280:8742-7
47. Smith AJ, de Vree JM, Ottenhoff R, et al. Hepatocyte-specific expression of the human MDR3 P-glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (-/-) mice. Hepatology 1998;28:530-6 (Pubitemid 28363683)
48. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-4 (Pubitemid 38233587)
49. Davis HR Jr, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004;279:33586-92 (Pubitemid 39063007)
50. Rosenblum SB, Huynh T, Afonso A, et al. Discovery of 1-(4-fluorophenyl)- (3R)-[3-(4-fluorophenyl)-(3S)- hydroxypropyl]-(4S)-(4 -hydroxyphenyl)- 2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem 1998;41:973-80
51. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-7 (Pubitemid 40800055)
52. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7 (Pubitemid 35335597)
53. Altmann SW, Davis HR Jr, Yao X, et al. The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochim Biophys Acta 2002;1580:77-93 (Pubitemid 34260848)
54. Mardones P, Quinones V, Amigo L, et al. Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient mice. J Lipid Res 2001;42:170-80 (Pubitemid 32206827)
55. Ge L, Wang J, Qi W, et al. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab 2008;7:508-19 (Pubitemid 351729203)
56. Carey MC, Small DM. The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man. J Clin Invest 1978;61:998-1026 (Pubitemid 8321078)
57. Wierzbicki AS. Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Curr Opin Lipidol 2010;21:352-8
58. Toth PP. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs 2010;70:1363-79
59. Moschetta A, Bookout AL, Mangelsdorf DJ. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 2004;10:1352-8 (Pubitemid 40022717)
60. Venneman NG, Van Erpecum KJ. Pathogenesis of gallstones. Gastroenterol Clin North Am 2010;39:171-83; vii
61. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006;113:2548-55 (Pubitemid 43948034)
62. Temel RE, Sawyer JK, Yu L, et al. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab 2010;12:96-102
63. van der Velde AE, Brufau G, Groen AK. Transintestinal cholesterol efflux. Curr Opin Lipidol 2010;21:167-71
64. Kruit JK, Plosch T, Havinga R, et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 2005;128:147-56 (Pubitemid 40039966)
65. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007;117:1968-78 (Pubitemid 47036331)
66. Wu JE, Basso F, Shamburek RD, et al. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. J Biol Chem 2004;279:22913-25 (Pubitemid 38685593)
67. Basso F, Freeman LA, Ko C, et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J Lipid Res 2007;48:114-26 (Pubitemid 46052903)
68. Wilund KR, Yu L, Xu F, et al. High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr-/- mice. J Lipid Res 2004;45:1429-36 (Pubitemid 39006970)
69. van der Velde AE, Vrins CL, van den Oever K, et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 2007;133:967-75 (Pubitemid 47374133)
70. Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev 2010;42:437-45
71. Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol 2008;14:7068-74